Oksana Koneva

Agenus reports 48 percent 3 year overall survival in ovarian cancer study

Agenus reports 48 percent 3 year overall survival in ovarian cancer study
Agenus posts ovarian cancer survival data

Agenus presented new three-year follow-up data from its Phase 1b trial of BOT plus BAL in patients with recurrent ovarian cancer. The estimated overall survival was 48 percent at three years, which remains unchanged from the two-year estimate in a heavily pretreated patient population.

The findings were shared at IGCSociety’s IGC2026 conference, providing updated insights into the potential long-term outcomes of the treatment protocol.

Agenus previously disclosed new details on the execution of its ROBBIN Phase 3 program and its BOT+BAL immunotherapy strategy in colorectal cancer in an earlier update. The company also presented long-term survivor and translational research findings on BOT plus BAL in colorectal cancer at SITC2026, as reported in another recent announcement. These prior reports focused on colorectal cancer, while the latest data addresses recurrent ovarian cancer outcomes.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.